Topline Phase 3 Results: HBI-8000 Plus Nivolumab Wow in Advanced Melanoma

HBI-8000 in combination with nivolumab (Opdivo, BMS) met its primary endpoint in a Phase 3 trial of patients with advanced melanoma, according to topline results reported by HUYABIO International.